You need JavaScript to view this

Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis

Abstract

In spite of its public health importance, our understanding of the mechanisms of breast carcinogenesis and progress is still evolving. The metabolic syndrome (MS) is a constellation of biochemical abnormalities including visceral adiposity, hyperglycemia, hyperinsulinemia, dyslipidemia and high blood pressure. The components of the MS have all been related to late-stage disease and even to a poor prognosis of breast cancer through multiple interacting mechanisms. In this review, we aim to present a summary of recent advances in the understanding of the contribution of the MS to breast cancer with the emphasis on the role of biomarkers of the MS in the prognosis of breast cancer.
Authors:
Zhu, Qiu-Li; Xu, Wang-Hong; [1]  Tao, Meng-Hua [2] 
  1. Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032 (China)
  2. Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY 14214 (United States)
Publication Date:
Apr 28, 2010
Product Type:
Journal Article
Resource Relation:
Journal Name: Cancers (Basel); Journal Volume: 2; Journal Issue: 2; Other Information: PMCID: PMC3835101; PMID: 24281091; PUBLISHER-ID: cancers-02-00721; OAI: oai:pubmedcentral.nih.gov:3835101; Copyright (c) 2010 by the authors; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).; Country of input: International Atomic Energy Agency (IAEA)
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOLOGICAL MARKERS; BLOOD PRESSURE; EPIDEMIOLOGY; MAMMARY GLANDS; NEOPLASMS; PUBLIC HEALTH
OSTI ID:
22432431
Country of Origin:
Switzerland
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 2072-6694; TRN: CH15$0325001873
Availability:
Available from http://dx.doi.org/10.3390/cancers2020721; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835101
Submitting Site:
CHN
Size:
page(s) 721-739
Announcement Date:
Feb 22, 2016

Citation Formats

Zhu, Qiu-Li, Xu, Wang-Hong, and Tao, Meng-Hua. Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis. Switzerland: N. p., 2010. Web. doi:10.3390/CANCERS2020721.
Zhu, Qiu-Li, Xu, Wang-Hong, & Tao, Meng-Hua. Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis. Switzerland. doi:10.3390/CANCERS2020721.
Zhu, Qiu-Li, Xu, Wang-Hong, and Tao, Meng-Hua. 2010. "Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis." Switzerland. doi:10.3390/CANCERS2020721. https://www.osti.gov/servlets/purl/10.3390/CANCERS2020721.
@misc{etde_22432431,
title = {Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis}
author = {Zhu, Qiu-Li, Xu, Wang-Hong, and Tao, Meng-Hua}
abstractNote = {In spite of its public health importance, our understanding of the mechanisms of breast carcinogenesis and progress is still evolving. The metabolic syndrome (MS) is a constellation of biochemical abnormalities including visceral adiposity, hyperglycemia, hyperinsulinemia, dyslipidemia and high blood pressure. The components of the MS have all been related to late-stage disease and even to a poor prognosis of breast cancer through multiple interacting mechanisms. In this review, we aim to present a summary of recent advances in the understanding of the contribution of the MS to breast cancer with the emphasis on the role of biomarkers of the MS in the prognosis of breast cancer.}
doi = {10.3390/CANCERS2020721}
journal = {Cancers (Basel)}
issue = {2}
volume = {2}
journal type = {AC}
place = {Switzerland}
year = {2010}
month = {Apr}
}